ArticleFrontiers in immunology2026
Recurrent single-CpG methylation differences and incomplete segregation in familial type 1 diabetes.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 1 diabetes (T1D) clusters within families, yet shared genetic susceptibility does not fully explain discordance among relatives. We investigated whether single CpG methylation differences recur independently across multiplex T1D families and whether methylation at these loci segregates with T1D status or relates to HLA class II risk haplotype dosage. Methods: Seventeen participants from three multiplex Arab families, including nine with T1D, underwent targeted bisulfite sequencing. Data from two sequencing runs were combined. Each pedigree was analysed independently. Unadjusted within-family analyses defined the cross-family recurrent set, requiring q<0.01, |Δβ|≥25% and concordant direction in all three families; age- and sex-adjusted analyses were then used to prioritise recurrent candidates. Candidate loci underwent pyrosequencing; public T1D transcriptomic datasets provided context for annotated genes. HLA genotyping determined risk haplotype dosage, and donor-level models examined associations with pyrosequencing methylation while accounting for family structure. Results: Unadjusted within-family analyses identified 22 recurrent CpGs with concordant methylation direction across the three pedigrees. Six of these retained the prespecified criteria after adjustment for age and sex and were prioritised for subsequent analyses. These mapped to Conclusion: These findings identify recurrent single-CpG methylation differences across multiplex T1D pedigrees but show incomplete individual-level segregation with disease. The six prioritised loci should therefore be considered exploratory methylation candidates whose temporal relationship with T1D and reproducibility require evaluation in larger independent and longitudinal family cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.